课题基金 / 基金详情

MICHELLAMINE B ANALOGS FOR TREATMENT OF HIV INFECTION

MICHELLAMINE B ANALOGS FOR TREATMENT OF HIV INFECTION
用于治疗 HIV 感染的米其胺 B 类似物
批准号:
6040611
负责人:
MARCIA I. DAWSON
金额:
$18.79万
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-03-01 至 2000-11-30

项目摘要

项目成果

MARCIA I. DAWSON的其他基金

相似基金

相关文献

中文摘要
翻译
描述:(改编自申请人摘要)更有效 需要开发治疗人类感染的疗法, 艾滋病病毒(艾滋病毒),它已造成获得性免疫缺陷的流行病, 免疫缺陷综合症(艾滋病)。目前,艾滋病病毒感染者可以 使用临床上可用的抗艾滋病毒药物治疗, 由于它们的毒副作用和 艾滋病毒对这些药物产生耐药性。的 二(萘四氢异喹啉)生物碱Michellamine B是一个新的生物碱 用于治疗这种疾病的治疗候选物。这种自然 产品不仅能抑制HIV 1型和2型在人体内的复制, T淋巴细胞在细胞培养中还能抑制HIV-1的复制 对目前可用的抗HIV核苷耐药的菌株 毒品由于在细胞培养中Michellamine B具有抗HIV活性, 在两种动物模型中,国家癌症研究所 目前正在进行药理学和毒理学研究, 为1期临床试验做准备。申请人提出一项 对Michellamine B类似物的构效关系进行了研究,以确定 抗病毒活性所需的药效基团和它们的最佳 空间定向这些信息将允许设计和 类似物的合成,其在合成上比 B具有更有利的治疗指数。此外,本发明还提供了一种方法, 对这些类似物的评价应提供关于 michellamines的抗病毒作用机制。两个类似物 在初步研究中设计和合成的Michellamine B抑制 HIV- 1(HTLV-IIIB株)在人体中的细胞病变效应 类淋巴母细胞系CEM-SS。两种类似物均抑制重组HIV 逆转录酶,这表明抑制这种酶可能 是其抗HIV活性的机制之一。两者都抑制了 蛋白激酶C活性。因此,抑制 一种重要病毒蛋白的磷酸化可能是另一种机制 的行动。
英文摘要
DESCRIPTION: (Adapted from Applicant's Abstract) More effective therapies need to be developed to treat infections by human immunodeficiency virus (HIV), which has caused the pandemic of acquired immune deficiency syndrome (AIDS). At present, HIV-infected patients can be treated with the clinically available anti-HIV drugs for only limited periods of time because of their toxic side effects and the ability of HIV to develop resistance to these drugs. The bis(naphthalenyltetrahydroisoquinoline) alkaloid, michellamine B is a new therapeutic candidate for the treatment of this disease. This natural product not only inhibits the replication of HIV types 1 and 2 in human T lymphocytes in cell culture but also inhibits the replication of HIV-1 strains that are resistant to the currently available anti-HIV nucleoside drugs. Because of the anti-HIV activity of michellamine B in cell culture and its low toxicity in two animal models, the National Cancer Institute is currently conducting pharmacological and toxicological studies in preparation for Phase 1 clinical trials. The applicants propose a structure-activity study on analogs of michellamine B to determine the pharmacophoric groups required for antiviral activity and their optimal spatial orientation. This information will then permit the design and synthesis of analogs that are more synthetically accessible than michellamine B and have a more favorable therapeutic index. In addition, evaluation of these analogs should provide valuable information on the mechanism of antiviral action of the michellamines. The two analogs of michellamine B designed and synthesized in preliminary studies inhibited the cytopathic effect of HIV- 1 (HTLV-IIIB strain) in the human lymphoblastoid cell line CEM-SS. Both analogs inhibited recombinant HIV reverse transcriptase, an indication that inhibition of this enzyme may be one of the mechanisms for their anti-HIV activity. Both also inhibited the activity of protein kinase C. Therefore, inhibition of the phosphorylation of an essential viral protein may be another mechanism of action.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Antioxidant activity of michellamine alkaloids.
米歇尔明生物碱的抗氧化活性。
DOI: --
发表时间: 1999
期刊: Anticancer research.
影响因子: --
作者: [White,EL, Ross,LJ, Hobbs,PD, Upender,V, Dawson,MI]
通讯作者: Dawson,MI
Michellamine alkaloids inhibit protein kinase C.
米歇尔明生物碱抑制蛋白激酶 C。
DOI: 10.1006/abbi.1999.1145
发表时间: 1999
期刊: Archives of biochemistry and biophysics.
影响因子: --
作者: [White,EL, Chao,WR, Ross,LJ, Borhani,DW, Hobbs,PD, Upender,V, Dawson,MI]
通讯作者: Dawson,MI
LRH-1 Antagonism: Impact on Estrogen-dependent Breast Cancer
LRH-1 Antagonism: Impact on Estrogen-dependent Breast Cancer
LRH-1 Antagonism: Impact on Estrogen-dependent Breast Cancer
Rexinoid Synergy in Prostate Cancer Apoptosis
海外基金